Natera, Inc. (NASDAQ:NTRA) Stock Has Average Target Price of $394.31

Shares of Natera, Inc. (NASDAQ:NTRA) have received an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation, seventeen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $391.69.

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. BTIG Research raised their price target on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research report on Tuesday, October 27th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. UBS Group increased their price objective on shares of Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Natera from $460.00 to $405.00 and set an “overweight” rating for the company in a report on Friday.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $310.67 on Wednesday. Natera has a 1 year low of $181.00 and a 1 year high of $437.41. The stock’s 50-day simple moving average is $380.25 and its 200-day simple moving average is $269.68. The firm has a market cap of $44.78 billion, a price-to-earnings ratio of -272.52 and a beta of 1.55.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.73%. The business had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same period in the prior year, the company posted ($0.64) EPS. The company’s revenue for the quarter was up 34.1% on a year-over-year basis. As a group, research analysts predict that Natera will post -1.14 EPS for the current year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,419 shares of Natera stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $409.77, for a total value of $1,401,003.63. Following the completion of the transaction, the insider directly owned 101,323 shares in the company, valued at approximately $41,519,125.71. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 302 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total value of $120,803.02. Following the completion of the sale, the insider directly owned 195,276 shares of the company’s stock, valued at approximately $78,112,352.76. This represents a 0.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 47,056 shares of company stock worth $17,760,989. Company insiders own 5.05% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Natera in the 2nd quarter valued at approximately $2,962,770,000. Aberdeen Group plc raised its stake in Natera by 26,462.7% during the 3rd quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock valued at $578,136,000 after acquiring an additional 1,393,528 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after acquiring an additional 11,793 shares during the period. Maverick Capital Ltd. boosted its position in Natera by 24.1% during the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after acquiring an additional 227,605 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Natera by 10.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after acquiring an additional 80,440 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.